These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21551263)

  • 1. Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.
    De Souza R; Zahedi P; Badame RM; Allen C; Piquette-Miller M
    Mol Cancer Ther; 2011 Jul; 10(7):1289-99. PubMed ID: 21551263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic strategies to overcome taxane resistance in cancer.
    Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
    Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoothened antagonists reverse taxane resistance in ovarian cancer.
    Steg AD; Katre AA; Bevis KS; Ziebarth A; Dobbin ZC; Shah MM; Alvarez RD; Landen CN
    Mol Cancer Ther; 2012 Jul; 11(7):1587-97. PubMed ID: 22553355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.
    Boyerinas B; Park SM; Murmann AE; Gwin K; Montag AG; Zillhardt M; Hua YJ; Lengyel E; Peter ME
    Int J Cancer; 2012 Apr; 130(8):1787-97. PubMed ID: 21618519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines.
    Naramoto H; Uematsu T; Uchihashi T; Doto R; Matsuura T; Usui Y; Uematsu S; Li X; Takahashi M; Yamaoka M; Furusawa K
    Int J Oncol; 2007 Feb; 30(2):393-401. PubMed ID: 17203221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The
    Yin B; Lu P; Liang J; Zhang W; Xin M; Pei K; Li Y
    J Int Med Res; 2019 Oct; 47(10):5256-5269. PubMed ID: 31638462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes.
    Zhang J; Zhang HD; Yao YF; Zhong SL; Zhao JH; Tang JH
    Cell Physiol Biochem; 2015; 36(6):2274-86. PubMed ID: 26279432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
    Sun X; Lou LG; Sui DH; Wu XH
    Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.
    Ricci JW; Lovato DM; Severns V; Sklar LA; Larson RS
    Mol Cancer Ther; 2016 Dec; 15(12):2853-2862. PubMed ID: 27671528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
    Chen Y; Bieber MM; Teng NN
    Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines.
    Schöndorf T; Neumann R; Benz C; Becker M; Riffelmann M; Göhring UJ; Sartorius J; von König CH; Breidenbach M; Valter MM; Hoopmann M; Di Nicolantonio F; Kurbacher CM
    Recent Results Cancer Res; 2003; 161():111-6. PubMed ID: 12528803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells.
    Reed K; Hembruff SL; Laberge ML; Villeneuve DJ; Côté GB; Parissenti AM
    Epigenetics; 2008 Sep; 3(5):270-80. PubMed ID: 19001875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer.
    De Souza R; Zahedi P; Moriyama EH; Allen CJ; Wilson BC; Piquette-Miller M
    Mol Cancer Ther; 2010 Jun; 9(6):1820-30. PubMed ID: 20530719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
    Talekar M; Ouyang Q; Goldberg MS; Amiji MM
    Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
    Liu G; Taylor SA; Marrinan CH; Hsieh Y; Bishop WR; Kirschmeier P; Long BJ
    Int J Cancer; 2009 Dec; 125(11):2711-20. PubMed ID: 19530253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.
    Wang SQ; Liu ST; Zhao BX; Yang FH; Wang YT; Liang QY; Sun YB; Liu Y; Song ZH; Cai Y; Li GF
    Oncotarget; 2015 Sep; 6(28):26142-60. PubMed ID: 26317651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.